Not Yet Recruiting PHASE2/PHASE3 INTERVENTIONAL 3-arm
NCT06863493
Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients
Study of the Safety and Effectiveness of Oral SFA-002 Compared to Oral Apremilast (Otezla) Tablets and Placebo in Mild to Severe Plaque Psoriasis
Sponsor: SFA Therapeutics
Conditions
Psoriasis (PsO)
Updated 1 time since 2025 Last updated: Mar 6, 2025 Started: Jun 1, 2025 Primary completion: Jun 1, 2026 Completion: Sep 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2/PHASE3 trial investigates Psoriasis (PsO) and is currently actively recruiting participants. SFA Therapeutics leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2/PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- SFA Therapeutics
Data source: SFA Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.